ImmuCell ImmuCell Announces Preliminary Sales Results for Second Quarter of 2018 For Immediate Release

ImmuCell Announces Preliminary Sales Results

Second Quarter of 2018

PORTLAND, Maine - July 10, 2018 - ImmuCell

Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that

develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy

and beef cattle, today announced preliminary sales results for its second quarter that ended on June 30, 2018.

Management Discussion:

"While it is not our standard practice to make projections

or to release financial results before our quarterly reviews are complete, we are releasing these sales figures now to show our

sales run-rate having shipped all of the $901,000 of orders for the bivalent formats of the First Defense

product line that were on backlog as of March 31, 2018," commented Michael F. Brigham, President and CEO. "While this

backlog did result in an unfavorable first quarter, the resolution of the backlog contributed to a very strong second quarter.

The results for the six-month period ended June 30, 2018 normalize for the timing impact of the shipping of this backlog between

the quarters, resulting in an 11% increase over the same period in 2017."

"We are still not able to meet the market demand for

Tri-Shield First Defense , but we are making the manufacturing process improvements necessary

to consistently produce adequate amounts of the complex rotavirus vaccine that is used to make this product," continued Mr.

Brigham. "We are making substantial progress in addressing the supply problem and intend to re-launch this new product at

the beginning of 2019."

Product Sales (unaudited):

Interested parties can access the conference call scheduled by the Company to review the complete second quarter results by dialing

(844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET Tuesday, August 14, 2018. A teleconference replay of

the call will be available for six days at (877) 344-7529 (toll free) or (412) 317-0088 (international), confirmation #10122008.

ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the

health and productivity of dairy and beef cattle. ImmuCell has developed products that provide significant, immediate immunity

to newborn dairy and beef livestock. The Company is developing a novel treatment for mastitis, the most significant cause of economic

loss to the dairy industry. Press releases and other information about the Company are available at: http://www.immucell.com.

Safe Harbor Statement:

This Press Release contains "forward-looking statements"

within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements

include, but are not limited to, any statements relating to: projections of future financial performance; projections about depreciation

expense and its impact on income for book and tax return purposes; the scope and timing of ongoing and future product development

work and commercialization of our products; future costs of product development efforts; the estimated prevalence rate of subclinical

mastitis; the expected efficacy of new products; estimates about the market size for our products; future market share of and revenue

generated by current products and products still in development; our ability to increase production output and reduce costs of

goods sold associated with our new product, Tri-Shield First Defense ;

the future adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships

to meet demand for our products on a timely basis; the efficiency and effectiveness of our manufacturing processes and related

technical issues; estimates about our production capacity; the future adequacy of our working capital and the availability and

cost of third party financing; the timing and outcome of pending or anticipated applications for regulatory approvals; future regulatory

requirements relating to our products; future expense ratios and margins; future compliance with bank debt covenants; future cost

of our variable rate interest expense on most of our bank debt; costs associated with sustaining compliance with current Good Manufacturing

Practice (cGMP) regulations in our current operations and attaining such compliance for the facility to produce the Drug Substance;

factors that may affect the dairy and beef industries and future demand for our products; implementation of international trade

tariffs that could reduce the export of dairy products weakening the price received by our customers for their product; our effectiveness

in competing against competitors within both our existing and our anticipated product markets; the cost-effectiveness of additional

sales and marketing expenditures and resources; anticipated changes in our manufacturing capabilities and efficiencies; anticipated

competitive and market conditions; and any other statements that are not historical facts. Forward-looking statements can be identified

by the use of words such as "expects", "may", "anticipates", "aims", "intends",

"would", "could", "should", "will", "plans", "believes",

"estimates", "targets", "projects", "forecasts" and similar words and expressions.

In addition, there can be no assurance that future developments affecting us will be those that we anticipate. Such statements

involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays

in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated product

markets, customer acceptance of our new and existing products, product performance, alignment between our manufacturing resources

and product demand, the uncertainties associated with product development and Drug Substance manufacturing, our potential reliance

upon third parties for financial support, products and services, changes in laws and regulations, decision making by regulatory

authorities, possible dilutive impacts on existing stockholders from any equity financing transactions in which we may engage,

currency values and fluctuations and other risks detailed from time to time in filings we make with the Securities and Exchange

Commission, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K.

Such statements are based on our current expectations, but actual results may differ materially due to various factors, including

the risk factors discussed above.